Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center
Bayer
M.D. Anderson Cancer Center
Washington University School of Medicine
National Cancer Centre, Singapore
Thomas Jefferson University